This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment.
Times:
01:46 Dicot Pharma
17:21 Allegro
Allegro
Allegro is a Belgium-based biomedical company which recently announced statistically significant improvements in pain and function in a 30-patient study of hydrocelin, a first-in-class nanotechnology injection for knee osteoarthritis (OA).
Rather than lubricating the joint like existing injectables such as hyaluronic acid or corticosteroids, hydrocelin uses cross-linked microparticles designed to physically restore the shock-absorbing mechanics of synovial fluid, thereby targeting a proposed root cause of OA rather than just masking symptoms.
Separately, Allegro just completed enrolment in a parallel European feasibility trial two months ahead of schedule. Topline safety/tolerability data are expected in H2 2026 and will inform a planned global registrational study.
Dicot Pharma
Dicot Pharma is developing the first innovation to erectile dysfunction in last 30 years. Virtually nothing has happened since Viagra and Cialis were introduced.
The company has recently been given the green light to start its phase IIb trials in the US, and trials are about to start in the EU, too.
The drug, LIB-01 has a completely different mode of action, which means a wider group of men can take it. Taking three pills means the drug will work spontaneously for eight weeks, meaning couples do not need to plan anything.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com